In young male mice on a high-fat diet, a 4-week anti-myostatin antibody treatment increased lean body mass by 7–9% and reduced fat mass by up to 35%, but did not improve insulin sensitivity.
See the scientific wording
In young male mice fed a high-fat diet, a 4-week treatment with an anti-myostatin antibody increased lean body mass by 7–9% and reduced adiposity by up to 35%, but did not improve insulin sensitivity, demonstrating that muscle hypertrophy induced by myostatin inhibition is insufficient to reverse diet-induced insulin resistance.
There's disagreement
Randomized trialsThe single study we reviewed is not enough to settle this claim.
What the research says
1 study reviewedSupporting (0)
No supporting studies found yet
We'll keep looking as more research is published.
Contradicting (1)
Cohort StudyAnimal2016
The study found that blocking myostatin in older mice improved both muscle and how well their bodies used insulin — but the claim says this doesn’t work in young mice. Since the study shows insulin sensitivity CAN improve with this treatment, it contradicts the claim’s conclusion.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Blocking myostatin makes muscles bigger, but in young mice eating a high-fat diet, fat tissue stays inflamed and resistant to insulin, so even with more muscle, the body cannot take up glucose properly.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 contradicting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In young male mice on a high-fat diet, a 4-week anti-myostatin antibody treatment increased lean body mass by 7–9% and reduced fat mass by up to 35%, but did not improve insulin sensitivity.
Mechanism
1 studyMaking muscles bigger with anti-myostatin treatment does not fix insulin resistance in young mice on a high-fat diet because the fat tissue stays inflamed and blocks insulin from working, even though the muscles are now larger and ready to take up more sugar.
Blocking myostatin makes muscles bigger, but in young mice eating a high-fat diet, fat tissue stays inflamed and resistant to insulin, so even with more muscle, the body cannot take up glucose properly.
Anti-myostatin antibody binds to and neutralizes myostatin, preventing its interaction with activin type II receptors on muscle cells
Inhibition of myostatin signaling reduces Smad2/3 phosphorylation, lifting suppression of muscle protein synthesis and triggering myofiber hypertrophy
Muscle hypertrophy increases total skeletal muscle mass by 7–9%, expanding the tissue volume capable of glucose uptake
Adipose tissue remains inflamed and exhibits impaired insulin signaling despite reduced fat mass, maintaining elevated free fatty acid levels and systemic inflammation
Persistent adipose tissue dysfunction suppresses insulin receptor substrate-1 phosphorylation and GLUT4 translocation in muscle, preventing increased glucose uptake despite greater muscle mass
Whole-body insulin sensitivity remains unchanged because insulin-stimulated glucose disposal is limited by adipose-driven insulin resistance, not muscle capacity
Evidence from Studies
Supporting (0)
Community contributions welcome
Contradicting (1)
Community contributions welcome
Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice
The study found that blocking myostatin in older mice improved both muscle and how well their bodies used insulin — but the claim says this doesn’t work in young mice. Since the study shows insulin sensitivity CAN improve with this treatment, it contradicts the claim’s conclusion.
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Anti-Myostatin Antibody Effects on Lean Mass, Adiposity, and Insulin Sensitivity in Animal Models of Diet-Induced Obesity
Population: Young male mice on high-fat diet; Intervention: Anti-myostatin antibody; Comparator: Placebo or isotype control; Outcomes: Lean body mass, adiposity, insulin sensitivity (HOMA-IR, glucose tolerance); Duration: 4 weeks; Inclusion: All peer-reviewed in vivo studies with standardized dosing and outcome measures.
Double-Blind Randomized Trial of Anti-Myostatin Antibody vs Placebo on Body Composition and Insulin Sensitivity in Young Male Mice on High-Fat Diet
Population: Young male mice on high-fat diet; Intervention: Anti-myostatin antibody; Comparator: Placebo; Outcomes: Lean body mass (DEXA), adiposity (fat mass %), insulin sensitivity (euglycemic clamp); Duration: 4 weeks; Design: Randomized, double-blinded, vehicle-controlled, n ≥ 10 per group.
Longitudinal Cohort Study of Anti-Myostatin Antibody Treatment and Metabolic Outcomes in Young Male Mice on High-Fat Diet
Population: Young male mice on high-fat diet; Intervention: Anti-myostatin antibody administered at baseline; Comparator: Untreated controls; Outcomes: Serial measurements of lean mass, fat mass, insulin sensitivity at weeks 0, 2, 4; Duration: 4 weeks; Design: Prospective, non-randomized, with repeated measures.
In Vitro Analysis of Myostatin Inhibition on Skeletal Muscle Hypertrophy and Adipocyte Insulin Signaling in Mouse Cell Lines
Population: Mouse C2C12 myoblasts and 3T3-L1 adipocytes; Intervention: Anti-myostatin antibody or siRNA knockdown; Comparator: Control IgG or scrambled siRNA; Outcomes: Myotube diameter, GLUT4 translocation, Akt phosphorylation; Duration: 72 hours; Design: Dose-response, time-course, pathway analysis.
Single-Center Pilot Study of Anti-Myostatin Antibody on Body Composition and Glucose Homeostasis in Young Male Mice on High-Fat Diet
Population: Young male C57BL/6 mice on high-fat diet; Intervention: Single dose of anti-myostatin antibody; Comparator: Saline control; Outcomes: Body composition (MRI), fasting glucose, insulin; Duration: 4 weeks; Design: Non-randomized, non-blinded, n=5–8 per group.